The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to ...

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.

Immune-mediated diseases specialist Alumis has announced positive top-line results from its Phase III ONWARD1 and ONWARD2 ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and greater patient access to advanced therapies. The shift from conventional ...

In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.

Arrowhead Pharmaceuticals disclosed that its gene-silencing candidates helped people with obesity lose fat, very early ...

Analysts lifted price targets and reaffirmed bullish ratings after the Phase 3 results. ・The new trial data showed strong skin clearance with results improving over time. ・Alumis outlined plans for an ...

For patients who may benefit from such scans, it's unclear whether including the spine as well as the sacroiliac joint ...

Challenges remain, like regulatory hurdles and funding, but our team's grit and your support as shareholders make me ...

Soothes blemishes: Ice can help reduce the swelling and redness of pimples and soothe irritated skin. Because swollen skin ...